ArticleObesity surgery2026
Application of the SF-BARI Score for Evaluating long-term Metabolic and Clinical Outcomes after Bariatric Surgery.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBariatric surgery is an effective treatment for severe obesity, resulting in significant weight loss and remission of obesity-related diseases. However, weight gain remains a challenge, potentially impacting long-term outcomes. The Swiss-Finnish BARIatric metabolic outcome score (SF-BARI) is a composite tool that integrates percentage total weight loss (%TWL), obesity associated disease remission, and operative complications rates to evaluate surgical optimal clinical response. This study assessed the associations between SF-BARI scores, obesity associated diseases remission, and weight gain 5 years after bariatric surgery.
methodsThis retrospective cohort study included 81 patients who underwent Roux-en-Y gastric bypass (RYGB) at a Portuguese hospital, with complete 5-year follow-up data. Data on weight, body mass index (BMI), %TWL, weight gain (> 5% of nadir weight), and remission of type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, and obstructive sleep apnea (OSA) were collected at baseline and at 1 year and 5 years post-surgery. SF-BARI scores were calculated to assess outcomes. Statistical analyses included t tests, chi-square tests, and regression models to explore associations between SF-BARI scores, weight gain, and obesity associated diseases remission.
resultsAt 1 year, the mean BMI decreased from 44.8 ± 5.1 kg/m² to 27.7 ± 3.8 kg/m² (p < 0.001), with a mean SF-BARI score of 103 ± 20.3 (good). At 5 years, the BMI increased to 30.6 ± 4.7 kg/m², 57.1% of patients experienced > 5% weight gain, and the SF-BARI score decreased to 93.8 ± 25.3 (good). Obesity associated diseases remission was significant, with 60.7% of hypertensive patients, 66.7% of diabetic patients, 50% of dyslipidemic patients, and 66.7% of OSA patients having improved disease control. No significant association was found between weight gain and obesity associated diseases control (p > 0.05). Greater % excess weight loss was the strongest predictor of higher SF-BARI scores (r²=0.596, p < 0.001), whereas weight gain and higher BMI were associated with lower scores (p < 0.001).
conclusionBariatric surgery yields durable improvements in weight and obesity associated diseases control at 5 years, despite frequent weight gain. The SF-BARI score effectively captures multidimensional outcomes, and the lack of association between weight gain and obesity associated diseases remission suggests weight-independent mechanisms. However, further studies are needed to validate the prognostic value of the SF-BARI in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.